These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22287818)

  • 1. ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
    Carson J; Haddad D; Bressman M; Fong Y
    Drugs Future; 2010; 35(3):183-195. PubMed ID: 22287818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children.
    Friedman GK; Beierle EA; Gillespie GY; Markert JM; Waters AM; Chen CY; Denton NL; Haworth KB; Hutzen B; Leddon JL; Streby KA; Wang PY; Cripe TP
    Mol Ther Oncolytics; 2015; 2():15016-. PubMed ID: 26436134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.
    Sanchala DS; Bhatt LK; Prabhavalkar KS
    Front Pharmacol; 2017; 8():270. PubMed ID: 28559846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
    Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
    J Virol; 2017 May; 91(10):. PubMed ID: 28250120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors.
    Abdoli Sh; Roohvand F; Teimoori-Toolabi L; Shokrgozar MA; Bahrololoumi M; Azadmanesh K
    Iran Biomed J; 2017 Jul; 21(4):206-17. PubMed ID: 28525954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncotarget Strategies For Herpes Simplex Virus-1.
    Zhang L; Tatsuya T; Nishiyama Y
    Curr Gene Ther; 2016; 16(2):130-43. PubMed ID: 27029942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.
    Cripe TP; Chen CY; Denton NL; Haworth KB; Hutzen B; Leddon JL; Streby KA; Wang PY; Markert JM; Waters AM; Gillespie GY; Beierle EA; Friedman GK
    Mol Ther Oncolytics; 2015; 2():15015-. PubMed ID: 26436135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
    Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicative oncolytic herpes simplex viruses in combination cancer therapies.
    Post DE; Fulci G; Chiocca EA; Van Meir EG
    Curr Gene Ther; 2004 Mar; 4(1):41-51. PubMed ID: 15032613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer.
    Matsumura S; Nakamori M; Tsuji T; Kato T; Nakamura M; Ojima T; Fukuhara H; Ino Y; Todo T; Yamaue H
    Oncotarget; 2021 Feb; 12(4):344-354. PubMed ID: 33659045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Hum Cell; 2002 Sep; 15(3):151-9. PubMed ID: 12703545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
    Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
    Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of non-replicative and oncolytic replication-selective HSV vectors.
    Epstein AL; Rabkin SD
    Trends Mol Med; 2024 Aug; 30(8):781-794. PubMed ID: 38886138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm.
    Coukos G; Courreges MC; Benencia F
    Curr Gene Ther; 2003 Apr; 3(2):113-25. PubMed ID: 12653405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 22 Novel Motifs of the Cell Entry Fusion Glycoprotein B of Oncolytic Herpes Simplex Viruses: Sequence Analysis and Literature Review.
    Shi F; Xin VW; Liu XQ; Wang YY; Zhang Y; Cheng JT; Cai WQ; Xiang Y; Peng XC; Wang X; Xin HW
    Front Oncol; 2020; 10():1386. PubMed ID: 32974139
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.